Timing of VV-ECMO therapy implementation influences prognosis of COVID-19 patients.

Raphael GiraudDavid LegouisBenjamin AssoulineAmandine De CharriereDumeng DecosterdMarie-Eve BrunnerMallory Moret-BochatayThierry FumeauxKarim Bendjelid

Published in: Physiological reports (2021)

The present results suggest that VV-ECMO can be safely utilized in appropriately selected COVID-19 patients with refractory hypoxemia. The main information for clinicians is that late VV-ECMO therapy (i.e., beyond the seventh day of mechanical ventilation) seems futile.

Keyphrases

acute respiratory distress syndrome
mechanical ventilation
extracorporeal membrane oxygenation
respiratory failure
sars cov
coronavirus disease
healthcare
intensive care unit
primary care
quality improvement
mesenchymal stem cells
social media
respiratory syndrome coronavirus
bone marrow
smoking cessation